Clairvoyant Therapeutics Raises More Than $3 Million in Seed Financing, Adds Bench Strength to Senior Leadership Team
Institutional investor support to fund next stage investigation of psilocybin therapy as treatment for alcohol use disorderRenowned addiction specialist Mark Tyndall MD ScD joins Clairvoyant as Chief Medical